Monteverde Law Firm Investigates Organon Sale to Sun Pharmaceuticals
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy OGN?
Source: Globenewswire
- Shareholder Recovery: Monteverde & Associates has recovered millions for shareholders, showcasing its strength as a Top 50 firm in the 2025 ISS Securities Class Action Services Report.
- Transaction Investigation: The firm is investigating the sale of Organon & Co. to Sun Pharmaceuticals, which proposes a cash acquisition of $14.00 per share, aiming to assess the fairness of the deal.
- Legal Service Transparency: Monteverde emphasizes that shareholders should inquire about a lawyer's experience in class actions and their historical success rates when selecting legal representation to ensure professional support.
- Contact Information Provided: The firm offers free consultations, allowing shareholders to contact Juan Monteverde via email or phone for more information, ensuring that shareholder rights are adequately protected.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy OGN?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on OGN
Wall Street analysts forecast OGN stock price to fall
5 Analyst Rating
0 Buy
1 Hold
4 Sell
Strong Sell
Current: 11.260
Low
5.00
Averages
8.50
High
12.00
Current: 11.260
Low
5.00
Averages
8.50
High
12.00
About OGN
Organon & Co. is a global healthcare company. The Company is engaged in developing and delivering health solutions through a portfolio of prescription therapies and medical devices within women's health, biosimilars and a franchise of established medicines across a range of therapeutic areas. It has a portfolio of approximately 70 medicines and products across a range of therapeutic areas. It has a portfolio of contraception and fertility brands, including Nexplanon, NuvaRing, and Follistim AQ. Its Biosimilars portfolio spans across immunology and oncology treatments. It also has a portfolio of established brands, including brands in cardiovascular, dermatology and non-opioid pain management. It sells these products through various channels, including drug wholesalers and retailers, hospitals, government agencies and managed health care providers, such as pharmacy benefit managers and other institutions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Market Volatility Amid Rising Oil Prices
- Oil Price Impact: The S&P 500 and Nasdaq 100 indices are under pressure today, with the former unchanged and the latter down 0.10%, as WTI crude oil prices surged over 2%, indicating market sensitivity to rising energy costs.
- Mixed Tech Stock Performance: Qualcomm's stock rose more than 3% due to reports of collaboration with OpenAI and MediaTek on smartphone processors, while Microsoft fell after announcing it would cease revenue payments to OpenAI, highlighting intensifying competition within the tech sector.
- Geopolitical Tensions: President Trump's cancellation of negotiations with Iran has led to a spike in oil prices, exacerbating the global energy crisis and raising concerns about the ongoing struggle for control over the Strait of Hormuz, which could impact future oil prices and supply chain stability.
- Economic Data and Expectations: The German consumer confidence index fell to a 3.25-year low, indicating economic weakness, while markets expect the Federal Reserve to keep interest rates unchanged this week, reflecting a cautious stance amid inflation and oil price fluctuations.
See More
Investor Rights Law Firm Investigates Multiple Companies
- Legal Investigation Launched: Halper Sadeh LLC is investigating Organon & Co. (NYSE:OGN) regarding its sale to Sun Pharmaceutical Industries Limited for $14.00 per share, which may involve breaches of fiduciary duties impacting shareholder confidence and company reputation.
- RE/MAX Transaction Scrutiny: The sale of RE/MAX Holdings, Inc. (NYSE:RMAX) to The Real Brokerage Inc. offers either 5.152 shares or $13.80 in cash per share, potentially limiting superior competing offers, prompting shareholders to consider their rights and options.
- XOMA Transaction Risks: XOMA Royalty Corporation (NASDAQ:XOMA) is involved in a sale to Ligand Pharmaceuticals Incorporated for $39.00 per share, with Halper Sadeh LLC possibly seeking increased compensation for shareholders, affecting the future shareholder structure of the company.
- Merger Impact Analysis: The merger between The Real Brokerage Inc. (NASDAQ:REAX) and RE/MAX will result in Real shareholders owning approximately 59% of the combined entity, potentially altering the competitive landscape and necessitating a reassessment of shareholder rights and risks post-merger.
See More
Investigation Alerts for Multiple Mergers
- XOMA Acquisition Deal: XOMA Royalty Corporation is set to be acquired by Ligand Pharmaceuticals for $39.00 per share, totaling approximately $739 million; however, this price is below its 52-week high of $42.38, raising concerns among shareholders about the fairness of the transaction.
- Organon Merger Case: Organon & Co. will be acquired by Sun Pharmaceutical for $14.00 per share in cash, with an enterprise valuation of $11.75 billion, and the investigation focuses on whether the Organon Board failed to treat shareholders fairly, potentially impacting shareholder rights.
- RE/MAX Acquisition Proposal: RE/MAX Holdings, Inc. will be acquired by The Real Brokerage, allowing shareholders to choose between 5.152 shares of the new company or $13.80 in cash per share, with investigations into whether the Board failed to handle the transaction fairly, affecting shareholder interests.
- Soleno Acquisition Investigation: Soleno Therapeutics, Inc. will be acquired by Neurocrine Biosciences for $53.00 per share, representing a total transaction value of approximately $2.9 billion, but this price is below its 52-week high of $90.32, raising questions about the Board's fairness in the deal.
See More
Johnson Fistel Investigates Organon Board for Fiduciary Breach
- Investigation Launched: Johnson Fistel, PLLP has initiated an investigation into whether the board members of Organon & Co. breached their fiduciary duties in connection with the proposed sale to Sun Pharmaceutical, aiming to protect shareholder rights.
- Transaction Details: On April 26, 2026, Organon announced a definitive agreement with Sun Pharmaceutical, where shareholders will receive $14 per share in cash, which may not reflect the true value of the company.
- Shareholder Value Concerns: The investigation focuses on whether the board conducted a fair process to maximize shareholder value, ensuring that shareholders receive fair consideration, which could impact future shareholder trust and corporate governance.
- Law Firm Background: Johnson Fistel is a nationally recognized shareholder rights law firm that has recovered approximately $90.725 million for clients in securities class actions, demonstrating its strength in advocating for investor rights.
See More
Monteverde Law Firm Investigates Organon Sale to Sun Pharmaceuticals
- Shareholder Recovery: Monteverde & Associates has recovered millions for shareholders, showcasing its strength as a Top 50 firm in the 2025 ISS Securities Class Action Services Report.
- Transaction Investigation: The firm is investigating the sale of Organon & Co. to Sun Pharmaceuticals, which proposes a cash acquisition of $14.00 per share, aiming to assess the fairness of the deal.
- Legal Service Transparency: Monteverde emphasizes that shareholders should inquire about a lawyer's experience in class actions and their historical success rates when selecting legal representation to ensure professional support.
- Contact Information Provided: The firm offers free consultations, allowing shareholders to contact Juan Monteverde via email or phone for more information, ensuring that shareholder rights are adequately protected.
See More
Meta Signs Landmark Solar Power Deal with Overview Energy
- Solar Power Agreement: Meta has signed a deal with start-up Overview Energy to secure 1 gigawatt of solar capacity, with commercial delivery expected by 2030, aimed at powering its extensive AI infrastructure and enhancing its competitive edge in the AI sector.
- Funding Strategy: To finance the $50 billion Hyperion project, Meta has reportedly secured a $29 billion financing package from PIMCO and Blue Owl Capital, highlighting the immense capital required to sustain its position in the AI arms race.
- Challenges in China: Meta faces significant hurdles as China's National Development and Reform Commission mandates the unwinding of its $2 billion acquisition of Manus, reflecting regulatory pressures on foreign investments in the AI sector and potentially hindering Meta's autonomous AI ambitions.
- Market Outlook: Despite these challenges, Meta is actively expanding its AI technology, striving to maintain a leading position in the global AI market, particularly in competition with Microsoft and Alphabet, ensuring its technological innovations remain at the forefront.
See More
Market Volatility Amid Rising Oil Prices
- Oil Price Impact: The S&P 500 and Nasdaq 100 indices are under pressure today, with the former unchanged and the latter down 0.10%, as WTI crude oil prices surged over 2%, indicating market sensitivity to rising energy costs.
- Mixed Tech Stock Performance: Qualcomm's stock rose more than 3% due to reports of collaboration with OpenAI and MediaTek on smartphone processors, while Microsoft fell after announcing it would cease revenue payments to OpenAI, highlighting intensifying competition within the tech sector.
- Geopolitical Tensions: President Trump's cancellation of negotiations with Iran has led to a spike in oil prices, exacerbating the global energy crisis and raising concerns about the ongoing struggle for control over the Strait of Hormuz, which could impact future oil prices and supply chain stability.
- Economic Data and Expectations: The German consumer confidence index fell to a 3.25-year low, indicating economic weakness, while markets expect the Federal Reserve to keep interest rates unchanged this week, reflecting a cautious stance amid inflation and oil price fluctuations.
See More
Investor Rights Law Firm Investigates Multiple Companies
- Legal Investigation Launched: Halper Sadeh LLC is investigating Organon & Co. (NYSE:OGN) regarding its sale to Sun Pharmaceutical Industries Limited for $14.00 per share, which may involve breaches of fiduciary duties impacting shareholder confidence and company reputation.
- RE/MAX Transaction Scrutiny: The sale of RE/MAX Holdings, Inc. (NYSE:RMAX) to The Real Brokerage Inc. offers either 5.152 shares or $13.80 in cash per share, potentially limiting superior competing offers, prompting shareholders to consider their rights and options.
- XOMA Transaction Risks: XOMA Royalty Corporation (NASDAQ:XOMA) is involved in a sale to Ligand Pharmaceuticals Incorporated for $39.00 per share, with Halper Sadeh LLC possibly seeking increased compensation for shareholders, affecting the future shareholder structure of the company.
- Merger Impact Analysis: The merger between The Real Brokerage Inc. (NASDAQ:REAX) and RE/MAX will result in Real shareholders owning approximately 59% of the combined entity, potentially altering the competitive landscape and necessitating a reassessment of shareholder rights and risks post-merger.
See More
Investigation Alerts for Multiple Mergers
- XOMA Acquisition Deal: XOMA Royalty Corporation is set to be acquired by Ligand Pharmaceuticals for $39.00 per share, totaling approximately $739 million; however, this price is below its 52-week high of $42.38, raising concerns among shareholders about the fairness of the transaction.
- Organon Merger Case: Organon & Co. will be acquired by Sun Pharmaceutical for $14.00 per share in cash, with an enterprise valuation of $11.75 billion, and the investigation focuses on whether the Organon Board failed to treat shareholders fairly, potentially impacting shareholder rights.
- RE/MAX Acquisition Proposal: RE/MAX Holdings, Inc. will be acquired by The Real Brokerage, allowing shareholders to choose between 5.152 shares of the new company or $13.80 in cash per share, with investigations into whether the Board failed to handle the transaction fairly, affecting shareholder interests.
- Soleno Acquisition Investigation: Soleno Therapeutics, Inc. will be acquired by Neurocrine Biosciences for $53.00 per share, representing a total transaction value of approximately $2.9 billion, but this price is below its 52-week high of $90.32, raising questions about the Board's fairness in the deal.
See More
Johnson Fistel Investigates Organon Board for Fiduciary Breach
- Investigation Launched: Johnson Fistel, PLLP has initiated an investigation into whether the board members of Organon & Co. breached their fiduciary duties in connection with the proposed sale to Sun Pharmaceutical, aiming to protect shareholder rights.
- Transaction Details: On April 26, 2026, Organon announced a definitive agreement with Sun Pharmaceutical, where shareholders will receive $14 per share in cash, which may not reflect the true value of the company.
- Shareholder Value Concerns: The investigation focuses on whether the board conducted a fair process to maximize shareholder value, ensuring that shareholders receive fair consideration, which could impact future shareholder trust and corporate governance.
- Law Firm Background: Johnson Fistel is a nationally recognized shareholder rights law firm that has recovered approximately $90.725 million for clients in securities class actions, demonstrating its strength in advocating for investor rights.
See More
Monteverde Law Firm Investigates Organon Sale to Sun Pharmaceuticals
- Shareholder Recovery: Monteverde & Associates has recovered millions for shareholders, showcasing its strength as a Top 50 firm in the 2025 ISS Securities Class Action Services Report.
- Transaction Investigation: The firm is investigating the sale of Organon & Co. to Sun Pharmaceuticals, which proposes a cash acquisition of $14.00 per share, aiming to assess the fairness of the deal.
- Legal Service Transparency: Monteverde emphasizes that shareholders should inquire about a lawyer's experience in class actions and their historical success rates when selecting legal representation to ensure professional support.
- Contact Information Provided: The firm offers free consultations, allowing shareholders to contact Juan Monteverde via email or phone for more information, ensuring that shareholder rights are adequately protected.
See More
Meta Signs Landmark Solar Power Deal with Overview Energy
- Solar Power Agreement: Meta has signed a deal with start-up Overview Energy to secure 1 gigawatt of solar capacity, with commercial delivery expected by 2030, aimed at powering its extensive AI infrastructure and enhancing its competitive edge in the AI sector.
- Funding Strategy: To finance the $50 billion Hyperion project, Meta has reportedly secured a $29 billion financing package from PIMCO and Blue Owl Capital, highlighting the immense capital required to sustain its position in the AI arms race.
- Challenges in China: Meta faces significant hurdles as China's National Development and Reform Commission mandates the unwinding of its $2 billion acquisition of Manus, reflecting regulatory pressures on foreign investments in the AI sector and potentially hindering Meta's autonomous AI ambitions.
- Market Outlook: Despite these challenges, Meta is actively expanding its AI technology, striving to maintain a leading position in the global AI market, particularly in competition with Microsoft and Alphabet, ensuring its technological innovations remain at the forefront.
See More
